{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:15Z","timestamp":1761941655513,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00c3\u00adfico e Tecnol\u00c3\u00b3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00c3\u00adfico e Tecnol\u00c3\u00b3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.vhri.2019.02.005","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T13:46:04Z","timestamp":1558100764000},"page":"95-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective"],"prefix":"10.1016","volume":"20","author":[{"given":"Helena H.L.","family":"Borba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Rochau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaby","family":"Sroczynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eimy","family":"Minowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2019.02.005_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bjid.2015.04.004","article-title":"Disease burden of chronic hepatitis C in Brazil","volume":"19","author":"Ferreira","year":"2015","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"10.1016\/j.vhri.2019.02.005_bib2","first-page":"189","article-title":"Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection","volume":"26","author":"Fernandez-Yunquera","year":"2013","journal-title":"Rev Esp Quimioter"},{"issue":"2","key":"10.1016\/j.vhri.2019.02.005_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4254\/wjh.v8.i2.92","article-title":"Chronic hepatitis C: this and the new era of treatment","volume":"8","author":"Bertino","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1016\/j.vhri.2019.02.005_bib4","doi-asserted-by":"crossref","first-page":"852968","DOI":"10.1155\/2015\/852968","article-title":"Chronic hepatitis C: an overview of evidence on epidemiology and management from a Brazilian perspective","volume":"2015","author":"Castro","year":"2015","journal-title":"Int J Hepatol"},{"issue":"1","key":"10.1016\/j.vhri.2019.02.005_bib5","doi-asserted-by":"crossref","DOI":"10.36876\/smjhrt.1003","article-title":"Barriers to directly acting antiviral agent use for chronic hepatitis C in South and South East Asia","volume":"1","author":"Ahmed","year":"2015","journal-title":"SM J Hepat Res Treat"},{"issue":"5","key":"10.1016\/j.vhri.2019.02.005_bib6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/0272989X12454577","article-title":"Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1","volume":"32","author":"Caro","year":"2012","journal-title":"Med Decis Making"},{"issue":"5","key":"10.1016\/j.vhri.2019.02.005_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/0272989X12455463","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3","volume":"32","author":"Siebert","year":"2012","journal-title":"Med Decis Making"},{"year":"2014","series-title":"Diretrizes Metodol\u00f3gicas. Diretriz de Avalia\u00e7\u00e3o Econ\u00f4mica. Secretariat of Science, Technology and Strategic Inputs","key":"10.1016\/j.vhri.2019.02.005_bib8"},{"issue":"13","key":"10.1016\/j.vhri.2019.02.005_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2147\/TCRM.S124663","article-title":"Rapid virological response of\u00a0telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study","volume":"2017","author":"Borba","year":"2017","journal-title":"Ther Clin Risk Manage"},{"year":"2013","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral C e Coinfec\u00e7\u00f5es (Gen\u00f3tipo 1 do HCV e Fibrose Avan\u00e7ada) - Suplemento 2. Secretary for the Vigilance on Health, Department of STD, AIDS and Viral Hepatitis","key":"10.1016\/j.vhri.2019.02.005_bib10"},{"year":"2011","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite Viral C e Coinfec\u00e7\u00f5es. Secretariat of Science, Technology and Strategic Inputs","key":"10.1016\/j.vhri.2019.02.005_bib11"},{"issue":"25","key":"10.1016\/j.vhri.2019.02.005_bib13","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.vhri.2019.02.005_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vhri.2019.02.005_bib15","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vhri.2019.02.005_bib16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/liv.12137","article-title":"Hospital mortality over time in patients with specific complications of cirrhosis","volume":"33","author":"Vergara","year":"2013","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.vhri.2019.02.005_bib17","first-page":"9","article-title":"Complica\u00e7\u00f5es da Cirrose Hep\u00e1tica\u2014ASCITE","volume":"1","author":"Bravo","year":"2016","journal-title":"Jornal Angolano de Ci\u00eancias de Sa\u00fade"},{"issue":"3","key":"10.1016\/j.vhri.2019.02.005_bib18","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2010.05.004","article-title":"EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis","volume":"53","year":"2010","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.vhri.2019.02.005_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/liv.13015","article-title":"Management of uninfected and infected ascites in cirrhosis","volume":"36","author":"Sola","year":"2016","journal-title":"Liver Int"},{"issue":"9","key":"10.1016\/j.vhri.2019.02.005_bib20","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMra0901512","article-title":"Management of varices and variceal hemorrhage in cirrhosis","volume":"362","author":"Garcia-Tsao","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vhri.2019.02.005_bib21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejca.2011.12.021","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"48","year":"2012","journal-title":"Eur J Cancer"},{"year":"2011","series-title":"Diretrizes Assistenciais\u2014Interna\u00e7\u00e3o para o Transplante de F\u00edgado: Admiss\u00e3o e Acompanhamento p\u00f3s operat\u00f3rio","key":"10.1016\/j.vhri.2019.02.005_bib22"},{"issue":"1","key":"10.1016\/j.vhri.2019.02.005_bib25","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1478-7547-1-8","article-title":"Generalized cost-effectiveness analysis for national-level priority-setting in the health sector","volume":"1","author":"Hutubessy","year":"2003","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"10.1016\/j.vhri.2019.02.005_bib26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1177\/0272989X12454579","article-title":"Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7","volume":"32","author":"Eddy","year":"2012","journal-title":"Med Decis Making"},{"issue":"13","key":"10.1016\/j.vhri.2019.02.005_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vhri.2019.02.005_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cgh.2012.10.006","article-title":"Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection","volume":"11","author":"Flamm","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.vhri.2019.02.005_bib29","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.cgh.2013.05.014","article-title":"Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration","volume":"11","author":"Chan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.vhri.2019.02.005_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1478-7547-11-25","article-title":"Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil","volume":"11","author":"Barros","year":"2013","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"10.1016\/j.vhri.2019.02.005_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/0003-4819-156-4-201202210-00005","article-title":"New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis","volume":"156","author":"Liu","year":"2012","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.vhri.2019.02.005_bib32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jvh.12278","article-title":"Management of treatment-naive chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of\u00a0treatment options","volume":"22","author":"Cortesi","year":"2015","journal-title":"J Viral Hepat"},{"issue":"3","key":"10.1016\/j.vhri.2019.02.005_bib33","doi-asserted-by":"crossref","first-page":"e25096","DOI":"10.1002\/jia2.25096","article-title":"The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil","volume":"21","author":"Luz","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"10.1016\/j.vhri.2019.02.005_bib34","first-page":"e00040717","article-title":"Cost-effectiveness thresholds and the Brazilian Unified National Health System","volume":"33","author":"Soarez","year":"2017","journal-title":"Cadernos de saude publica"},{"issue":"5","key":"10.1016\/j.vhri.2019.02.005_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2217\/cer.15.38","article-title":"Systematic overview of cost-effectiveness thresholds in ten countries across four continents","volume":"4","author":"Schwarzer","year":"2015","journal-title":"J Comp Eff Res"},{"year":"2018","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es - Relat\u00f3rio de Recomenda\u00e7\u00e3o. Secretariat of Science, Technology and Strategic Inputs","key":"10.1016\/j.vhri.2019.02.005_bib36"},{"issue":"3","key":"10.1016\/j.vhri.2019.02.005_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.7326\/M15-0320","article-title":"Limited access to new hepatitis C virus treatment under state Medicaid programs","volume":"163","author":"Canary","year":"2015","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.vhri.2019.02.005_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b16-00941","article-title":"Risk factors for treatment discontinuation caused by adverse events when using telaprevir, peginterferon, and ribavirin to treat chronic hepatitis C: a real-world retrospective cohort study","volume":"40","author":"Ide","year":"2017","journal-title":"Biol Pharm Bull"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109919300573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109919300573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:11:28Z","timestamp":1761941488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109919300573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":35,"alternative-id":["S2212109919300573"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2019.02.005","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2019.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}